Biotech

All Articles

Bicara, Zenas find IPOs to press late-phase assets towards market

.Bicara Therapies and also Zenas Biopharma have actually provided clean impetus to the IPO market al...

Genentech to shut cancer immunology research study team

.Genentech is going to close its cancer immunology research department, and also unit mind and promi...

Kezar falls sound cyst however to confirm its own truly worth in period 1 trial

.Kezar Life Sciences is actually losing its own dim stage 1 solid lump drug as the biotech goes all-...

Acelyrin goes down izokibep, lets go 3rd of personnel

.In spite of izokibep maintaining its newfound winning touch in the clinic, Acelyrin is no longer pa...

Rivus' phase 2 obesity-related heart failure trial hits endpoint

.Rivus Pharmaceuticals has plumped up the potential customers of its own fat-busting, muscle-sparing...

Ovid stops preclinical job, IV plan after soticlestat fall short

.Ovid Therapy actually uncovered last month that it was trimming its own headcount as the provider g...

Eli Lilly opens $700M nucleic acid R&ampD center in Boston Port

.Eli Lilly has opened a $700 thousand R&ampD center in the Boston Port, improving its RNA as well as...

Boundless Bio produces 'modest' layoffs 5 months after $100M IPO

.Simply five months after safeguarding a $one hundred million IPO, Boundless Bio is currently giving...

Halda's $126M will progress 'secure and also eliminate' lump medicines

.The preliminary phases of oncology R&ampD aren't except fascinating brand new techniques, as well a...

Lykos 'disappointments' not disclosing study transgressions along with author

.Psychopharmacology has drawn three posts regarding midstage professional test records examining Lyk...